DBTX — Decibel Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- $123.37m
- $45.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.05 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -73.4% | ||
| Return on Equity | -62.93% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 11.35 | 5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Directors
- William Carson NEC (62)
- Laurence Reid PRE (57)
- Gabriel Corfas CFD
- M. Charles Liberman CFD
- Ulrich Mueller CFD
- Elisabeth Leiderman CFO (44)
- Anna Trask CHO (63)
- John Lee EVP (53)
- Neil Exter IND (62)
- Alison Finger IND
- Matthew Foy IND (40)
- Saraswathy Nochur IND
- Peter Thompson IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- November 26th, 2013
- Public Since
- February 12th, 2021
- No. of Shareholders
- 86
- No. of Employees
- 68
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 25,014,984
- Address
- 1325 Boylston Street, Suite 500, BOSTON, 02215
- Web
- https://www.decibeltx.com/
- Phone
- +1 6173708701
- Auditors
- Ernst & Young LLP
Upcoming Events for DBTX
Q3 2023 Decibel Therapeutics Inc Earnings Release
Similar to DBTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Decibel Therapeutics share price?
As of Today at 01:06 UTC, shares in Decibel Therapeutics are trading at $2.93. This share price information is delayed by 15 minutes.
How has the Decibel Therapeutics share price performed this year?
Shares in Decibel Therapeutics last closed at $2.93 and the price had moved by -41.52% over the past 365 days. In terms of relative price strength the Decibel Therapeutics share price has underperformed the S&P500 Index by -49.79% over the past year.
What are the analyst and broker recommendations for Decibel Therapeutics?
The overall consensus recommendation for Decibel Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Decibel Therapeutics dividend yield?
Decibel Therapeutics does not currently pay a dividend.
Does Decibel Therapeutics pay a dividend?
Decibel Therapeutics does not currently pay a dividend.
When does Decibel Therapeutics next pay dividends?
Decibel Therapeutics does not currently pay a dividend.
How do I buy Decibel Therapeutics shares?
To buy shares in Decibel Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Decibel Therapeutics?
As of the previous close price of $2.93, shares in Decibel Therapeutics had a market capitalisation of $73.79m.
Where are Decibel Therapeutics shares listed?
Here are the trading details for Decibel Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DBTX
What kind of share is Decibel Therapeutics?
Based on an overall assessment of its quality, value and momentum Decibel Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Decibel Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Decibel Therapeutics is $14.30. That is 388.14% above the last closing price of $2.93.
Analysts covering Decibel Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.14 for the next financial year.
What is the trend in the Decibel Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Decibel Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -16.31%.
As of the last closing price of $2.93, shares in Decibel Therapeutics were trading -13.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Decibel Therapeutics PE Ratio?
The Decibel Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Decibel Therapeutics?
Decibel Therapeutics' management team is headed by:
- William Carson - NEC
- Laurence Reid - PRE
- Gabriel Corfas - CFD
- M. Charles Liberman - CFD
- Ulrich Mueller - CFD
- Elisabeth Leiderman - CFO
- Anna Trask - CHO
- John Lee - EVP
- Neil Exter - IND
- Alison Finger - IND
- Matthew Foy - IND
- Saraswathy Nochur - IND
- Peter Thompson - IND